Debbie Hart, CEO of BioNJ, felt excited when Governor Phil Murphy mentioned the life science industry in his recent State of the State address.
Even though it wasn’t the main focus, Hart appreciated the acknowledgment. The governor pointed out how New Jersey has earned the nickname “the medicine chest of the world.” He highlighted that our state has more engineers and scientists per person than any other place in the world.
“BioNJ is glad to see Gov. Murphy recognize how important innovation is for New Jersey’s economy,” Hart said. “We are eager to partner with the governor and lawmakers to keep New Jersey a hub for innovation in life sciences.”
Hart also noted that the theme of affordability is crucial. She hopes the Legislature will continue to tackle the practices of pharmacy benefit managers (PBMs), who significantly influence the prices of medications.
“We will work with lawmakers to push forward policies that lower costs while encouraging innovation. This includes supporting S3818 and A4953, which target various PBM practices. Our goal is to make medicine affordable for everyone,” Hart explained.
Looking ahead, Hart believes in the value of proactive measures. She quoted the governor: “The best way to predict the future is to create it.” As advocates for an industry leading the country in FDA approvals, BioNJ remains committed to this vision. After all, patients can’t wait for the help they need.
